NCT05501717
进行中（未招募）
1 期
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study of Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Subcutaneous ALXN2030 in Healthy Participants
概览
- 阶段
- 1 期
- 干预措施
- ALXN2030
- 疾病 / 适应症
- Healthy
- 发起方
- Alexion Pharmaceuticals, Inc.
- 入组人数
- 48
- 试验地点
- 1
- 主要终点
- Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)
- 状态
- 进行中（未招募）
- 最后更新
- 2个月前
概览
简要总结
The primary purpose of this study is to assess the safety and tolerability of single ascending doses of ALXN2030 in healthy participants.
详细描述
Approximately 48 healthy adult participants (36 participants will be on ALXN2030 and 12 participants will be on placebo) are expected to be enrolled.
研究者
入排标准
入选标准
- •Healthy participants
- •QTcF ≤ 450 msec at Screening and on admission (ie, on Day -1).
- •Participants of Japanese descent are defined as: First generation (born to 2 Japanese parents and 4 Japanese grandparents).
- •Participants of Japanese descent must be between 20 and 60 years of age.
- •BMI within the range 18-32kg/m2 (inclusive) at Screening.
排除标准
- •Current or recurrent disease
- •Current or relevant history of physical or psychiatric illness.
- •Any other significant disease or disorder that, in the opinion of the Investigator, may put the participant at risk.
- •Female participants who are pregnant or breastfeeding.
- •Major surgery or hospitalization within 90 days prior to dosing on Day
- •History of allergy or hypersensitivity to an oligonucleotide or GalNAc moiety or any excipients of ALXN2030.
研究组 & 干预措施
ALXN2030 Dose A
ALXN2030 will be administered as a single dose.
干预措施: ALXN2030
ALXN2030 Dose B
ALXN2030 will be administered as a single dose.
干预措施: ALXN2030
ALXN2030 Dose C
ALXN2030 will be administered as a single dose.
干预措施: ALXN2030
ALXN2030 Dose D
ALXN2030 will be administered as a single dose.
干预措施: ALXN2030
ALXN2030 Dose E
ALXN2030 will be administered as a single dose.
干预措施: ALXN2030
Placebo
Placebo will be administered as a single dose.
干预措施: Placebo
结局指标
主要结局
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)
时间窗: Day 1 through through study completion, an average of 1 year
次要结局
- Maximum Observed Plasma Concentration (Cmax)(Days 1 (predose; end of infusion (EOI); and 0.25, 0.5, 1, 2, 4, 6, 8, and 12 hours post-EOI), 2, 3, 5, 8, 15, 22, 29, 36, 43, 50, 57, 71, 85, 99, and 127)
- Time to Maximum Observed Plasma Concentration (Tmax)(Days 1 (predose; EOI; and 0.25, 0.5, 1, 2, 4, 6, 8, and 12 hours post-EOI), 2, 3, 5, 8, 15, 22, 29, 36, 43, 50, 57, 71, 85, 99, and 127)
- Area Under the Plasma Concentration Versus Time Curve From Time 0 (Dosing) to the Last Quantifiable Concentration (AUCt)(Days 1 (predose; EOI; and 0.25, 0.5, 1, 2, 4, 6, 8, and 12 hours post-EOI), 2, 3, 5, 8, 15, 22, 29, 36, 43, 50, 57, 71, 85, 99, and 127)
- Change from Baseline in Plasma Concentration of Complement Component 3 (C3) Protein(Baseline (Day 1) and study completion, an average of 1 year)
- Change from Baseline in Serum Complement Functional Activity(Baseline (Day 1) and Day 127)
- Number of Participants With Treatment-Emergent Antidrug Antibodies (ADAs)(Days 1 through study completion, an average of 1 year)
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study to Examine the Safety and Tolerability of Single Ascending Doses of REGN2477Healthy VolunteersNCT02870400Regeneron Pharmaceuticals41
已完成
1 期
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB100 Administered Orally to Adults With Amyotrophic Lateral SclerosisAmyotrophic Lateral SclerosisNCT03945279Biogen49
已完成
1 期
A Study to Evaluate ALN-AGT01 RVR in Adult Healthy VolunteersHealthy VolunteersNCT06675565Alnylam Pharmaceuticals42
已完成
1 期
A Study to Test the Safety, Pharmacokinetics, and Efficacy of UCB9741 in Healthy Study Participants and in Study Participants With Atopic DermatitisAtopic DermatitisNCT04643457UCB Biopharma SRL107
已完成
1 期
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Inhaled CHF10073 After Single and Multiple Doses in Healthy Volunteers and the Effect of Itraconazole on CHF10073 ExposurePulmonary FibrosisNCT06746064Chiesi Farmaceutici S.p.A.155